Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.

Kitabi EN, Minzi OMS, Mugusi S, Sasi P, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E.

Sci Rep. 2018 Nov 5;8(1):16316. doi: 10.1038/s41598-018-34674-3.

2.

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.

Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, Bakari M, Bertilsson L, Burhenne J, Sandstrom E, Aklillu E.

Eur J Clin Pharmacol. 2018 Nov;74(11):1405-1415. doi: 10.1007/s00228-018-2499-0. Epub 2018 Jul 12.

3.

Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.

Molanaei H, Qureshi AR, Heimbürger O, Lindholm B, Diczfalusy U, Anderstam B, Bertilsson L, Stenvinkel P.

BMC Pharmacol Toxicol. 2018 Jun 25;19(1):33. doi: 10.1186/s40360-018-0221-6.

4.

N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians.

Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Djordjevic N.

Eur J Clin Pharmacol. 2018 Jul;74(7):903-911. doi: 10.1007/s00228-018-2448-y. Epub 2018 Mar 27.

5.

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.

Habtewold A, Aklillu E, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Owen JS.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00207-17. doi: 10.1128/AAC.00207-17. Print 2017 Aug.

6.

Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease.

Goktas MT, Karaca RO, Kalkisim S, Cevik L, Kilic L, Akdogan A, Babaoglu MO, Bozkurt A, Bertilsson L, Yasar U.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):266-271. doi: 10.1111/bcpt.12710.

7.

Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.

Nylén H, Habtewold A, Makonnen E, Yimer G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E.

Medicine (Baltimore). 2016 Aug;95(34):e4631. doi: 10.1097/MD.0000000000004631.

8.

Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.

Habtewold A, Aklillu E, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Owen JS, Burhenne J.

J Clin Pharmacol. 2016 Dec;56(12):1538-1549. doi: 10.1002/jcph.756. Epub 2016 May 29.

PMID:
27125860
9.

The Psychostimulant Khat (Catha edulis) Inhibits CYP2D6 Enzyme Activity in Humans.

Bedada W, de Andrés F, Engidawork E, Pohanka A, Beck O, Bertilsson L, Llerena A, Aklillu E.

J Clin Psychopharmacol. 2015 Dec;35(6):694-9. doi: 10.1097/JCP.0000000000000413.

PMID:
26444948
10.

Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?

Goktaş MT, Hatta F, Karaca O, Kalkisim S, Kilic L, Akdogan A, Babaoglu MO, Bozkurt A, Helldén A, Bertilsson L, Yasar U.

Eur J Clin Pharmacol. 2015 Oct;71(10):1223-8. doi: 10.1007/s00228-015-1899-7. Epub 2015 Aug 2.

PMID:
26233334
11.

Genetic and Clinical Factors Affecting Plasma Clozapine Concentration.

Olsson E, Edman G, Bertilsson L, Hukic DS, Lavebratt C, Eriksson SV, Ösby U.

Prim Care Companion CNS Disord. 2015 Feb 19;17(1). doi: 10.4088/PCC.14m01704. eCollection 2015.

12.

Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex.

Hatta FH, Lundblad M, Ramsjo M, Kang JH, Roh HK, Bertilsson L, Eliasson E, Aklillu E.

OMICS. 2015 Jun;19(6):346-53. doi: 10.1089/omi.2015.0022. Epub 2015 May 15.

PMID:
25977991
13.

Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.

Habtewold A, Makonnen E, Amogne W, Yimer G, Aderaye G, Bertilsson L, Burhenne J, Aklillu E.

Pharmacogenomics. 2015;16(10):1047-64. doi: 10.2217/pgs.15.35. Epub 2015 Apr 1.

14.

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.

Ngaimisi E, Minzi O, Mugusi S, Sasi P, Riedel KD, Suda A, Ueda N, Bakari M, Janabi M, Mugusi F, Bertilsson L, Burhenne J, Aklillu E, Diczfalusy U.

J Antimicrob Chemother. 2014 Dec;69(12):3311-9. doi: 10.1093/jac/dku286. Epub 2014 Aug 4.

PMID:
25096076
15.

Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives.

Nylén H, Björkhem-Bergman L, Ekström L, Roh HK, Bertilsson L, Eliasson E, Lindh JD, Diczfalusy U.

Basic Clin Pharmacol Toxicol. 2014 Oct;115(4):366-71. doi: 10.1111/bcpt.12230. Epub 2014 Apr 11.

16.

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.

Mannheimer B, Holm J, Koukel L, Bertilsson L, Osby U, Eliasson E.

Eur J Clin Pharmacol. 2014 Jun;70(6):695-9. doi: 10.1007/s00228-014-1664-3. Epub 2014 Mar 20.

PMID:
24643635
17.

Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.

Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U.

Drug Metab Pharmacokinet. 2014;29(4):352-5. Epub 2014 Feb 11.

18.

High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.

Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M.

OMICS. 2014 Jul;18(7):446-53. doi: 10.1089/omi.2013.0140. Epub 2013 Dec 31.

19.

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.

Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J.

PLoS One. 2013 Jul 5;8(7):e67946. doi: 10.1371/journal.pone.0067946. Print 2013.

20.

Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin.

Björkhem-Bergman L, Bäckström T, Nylén H, Rönquist-Nii Y, Bredberg E, Andersson TB, Bertilsson L, Diczfalusy U.

Drug Metab Dispos. 2013 Aug;41(8):1488-93. doi: 10.1124/dmd.113.052316. Epub 2013 May 14.

PMID:
23674608
21.

Disease course, outcome, and predictors of outcome in a population-based juvenile chronic arthritis cohort followed for 17 years.

Bertilsson L, Andersson-Gäre B, Fasth A, Petersson IF, Forsblad-D'elia H.

J Rheumatol. 2013 May;40(5):715-24. doi: 10.3899/jrheum.120602. Epub 2013 Feb 15.

PMID:
23418376
22.

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.

Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E.

Pharmacogenomics J. 2013 Dec;13(6):484-9. doi: 10.1038/tpj.2012.46. Epub 2012 Oct 23.

PMID:
23089673
23.

Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans.

Djordjevic N, Carrillo JA, van den Broek MP, Kishikawa J, Roh HK, Bertilsson L, Aklillu E.

Drug Metab Pharmacokinet. 2013;28(2):93-7. Epub 2012 Jul 24.

24.

UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.

Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, Molden E, Eliasson E.

Clin Pharmacol Ther. 2012 Aug;92(2):221-7. doi: 10.1038/clpt.2012.46. Epub 2012 Jun 20.

PMID:
22713701
25.

A 5-year prospective population-based study of juvenile chronic arthritis: onset, disease process, and outcome.

Bertilsson L, Andersson-Gäre B, Fasth A, Forsblad-d'Elia H.

Scand J Rheumatol. 2012 Oct;41(5):379-82. doi: 10.3109/03009742.2012.677472. Epub 2012 May 29.

PMID:
22639832
26.

The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans.

Helldén A, Panagiotidis G, Johansson P, Waters N, Waters S, Tedroff J, Bertilsson L.

Eur J Clin Pharmacol. 2012 Sep;68(9):1281-6. doi: 10.1007/s00228-012-1248-z. Epub 2012 Mar 8.

PMID:
22399238
27.

Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.

Hatta FH, Teh LK, Helldén A, Hellgren KE, Roh HK, Salleh MZ, Aklillu E, Bertilsson L.

Eur J Clin Pharmacol. 2012 Jul;68(7):1033-42. doi: 10.1007/s00228-012-1210-0. Epub 2012 Feb 1.

PMID:
22294058
28.

Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.

Teh LK, Bertilsson L.

Drug Metab Pharmacokinet. 2012;27(1):55-67. Epub 2011 Dec 20. Review.

29.

Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation.

Molanaei H, Stenvinkel P, Qureshi AR, Carrero JJ, Heimbürger O, Lindholm B, Diczfalusy U, Odar-Cederlöf I, Bertilsson L.

Eur J Clin Pharmacol. 2012 May;68(5):571-7. doi: 10.1007/s00228-011-1163-8. Epub 2011 Dec 9.

PMID:
22159869
30.

Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans.

Djordjevic N, Carrillo JA, Roh HK, Karlsson S, Ueda N, Bertilsson L, Aklillu E.

J Clin Pharmacol. 2012 Oct;52(10):1527-34. Epub 2011 Nov 21.

PMID:
22105431
31.

Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E.

Clin Pharmacol Ther. 2011 Sep;90(3):406-13. doi: 10.1038/clpt.2011.129. Epub 2011 Aug 3.

PMID:
21814190
32.

Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol.

Nylén H, Sergel S, Forsberg L, Lindemalm S, Bertilsson L, Wide K, Diczfalusy U.

Eur J Clin Pharmacol. 2011 Jul;67(7):715-22. doi: 10.1007/s00228-010-0984-1. Epub 2011 Jan 19.

PMID:
21246351
33.

4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.

Diczfalusy U, Nylén H, Elander P, Bertilsson L.

Br J Clin Pharmacol. 2011 Feb;71(2):183-9. doi: 10.1111/j.1365-2125.2010.03773.x. Review.

34.

CYP2D6, serotonin, and suicide--a relationship?

Bertilsson L.

Clin Pharmacol Ther. 2010 Sep;88(3):304-5. doi: 10.1038/clpt.2010.144. No abstract available.

PMID:
20725080
35.

Clinically significant CYP2C inhibition by noscapine but not by glucosamine.

Rosenborg S, Stenberg M, Otto S, Ostervall J, Masquelier M, Yue QY, Bertilsson L, Eliasson E.

Clin Pharmacol Ther. 2010 Sep;88(3):343-6. doi: 10.1038/clpt.2010.107. Epub 2010 Jul 28.

PMID:
20668444
36.

CYP2D6, serotonin and suicide.

Ahlner J, Zackrisson AL, Lindblom B, Bertilsson L.

Pharmacogenomics. 2010 Jul;11(7):903-5. doi: 10.2217/pgs.10.84. No abstract available.

37.

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.

Ramsjö M, Aklillu E, Bohman L, Ingelman-Sundberg M, Roh HK, Bertilsson L.

Eur J Clin Pharmacol. 2010 Sep;66(9):871-7. doi: 10.1007/s00228-010-0835-0. Epub 2010 May 25.

PMID:
20499227
38.

Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9.

Helldén A, Bergman U, Engström Hellgren K, Masquelier M, Nilsson Remahl I, Odar-Cederlöf I, Ramsjö M, Bertilsson L.

Eur J Clin Pharmacol. 2010 Aug;66(8):791-5. doi: 10.1007/s00228-010-0820-7. Epub 2010 Apr 20.

PMID:
20405111
39.

Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.

Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, Osby U.

Eur J Clin Pharmacol. 2010 May;66(5):465-74. doi: 10.1007/s00228-009-0783-8. Epub 2010 Feb 9.

PMID:
20143052
40.

Influence of the CYP2D6 polymorphism and hemodialysis on codeine disposition in patients with end-stage renal disease.

Molanaei H, Carrero JJ, Heimbürger O, Nordfors L, Lindholm B, Stenvinkel P, Odar-Cederlöf I, Bertilsson L.

Eur J Clin Pharmacol. 2010 Mar;66(3):269-73. doi: 10.1007/s00228-009-0759-8. Epub 2009 Nov 26.

PMID:
19940985
41.

Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers.

Ghotbi R, Gomez A, Milani L, Tybring G, Syvänen AC, Bertilsson L, Ingelman-Sundberg M, Aklillu E.

Pharmacogenomics J. 2009 Jun;9(3):208-17. doi: 10.1038/tpj.2009.4. Epub 2009 Mar 10.

PMID:
19274061
42.

MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs.

Hilli J, Heikkinen T, Rontu R, Lehtimäki T, Kishida I, Aklillu E, Bertilsson L, Vahlberg T, Laine K.

Eur Neuropsychopharmacol. 2009 May;19(5):363-70. doi: 10.1016/j.euroneuro.2009.01.006. Epub 2009 Feb 14.

PMID:
19223155
43.

Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.

Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen KJ, Korhonen T, Neuvonen PJ, Laine K.

Antimicrob Agents Chemother. 2009 Feb;53(2):587-92. doi: 10.1128/AAC.00530-08. Epub 2008 Nov 17.

44.

4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.

Diczfalusy U, Kanebratt KP, Bredberg E, Andersson TB, Böttiger Y, Bertilsson L.

Br J Clin Pharmacol. 2009 Jan;67(1):38-43. doi: 10.1111/j.1365-2125.2008.03309.x. Epub 2008 Nov 6.

45.

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.

Ohlsson Rosenborg S, Mwinyi J, Andersson M, Baldwin RM, Pedersen RS, Sim SC, Bertilsson L, Ingelman-Sundberg M, Eliasson E.

Eur J Clin Pharmacol. 2008 Dec;64(12):1175-9. doi: 10.1007/s00228-008-0529-z. Epub 2008 Jul 25.

PMID:
18654768
46.

Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.

Kanebratt KP, Diczfalusy U, Bäckström T, Sparve E, Bredberg E, Böttiger Y, Andersson TB, Bertilsson L.

Clin Pharmacol Ther. 2008 Nov;84(5):589-94. doi: 10.1038/clpt.2008.132. Epub 2008 Jul 23.

PMID:
18650803
47.

CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.

Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L.

Eur J Clin Pharmacol. 2008 Dec;64(12):1163-73. doi: 10.1007/s00228-008-0525-3. Epub 2008 Jul 22.

PMID:
18648788
48.

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.

Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N.

Ann Rheum Dis. 2009 May;68(5):648-53. doi: 10.1136/ard.2007.085852. Epub 2008 May 8.

PMID:
18467516
49.

CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.

Josephson F, Bertilsson L, Böttiger Y, Flamholc L, Gisslén M, Ormaasen V, Sönnerborg A, Diczfalusy U.

Eur J Clin Pharmacol. 2008 Aug;64(8):775-81. doi: 10.1007/s00228-008-0492-8. Epub 2008 May 6.

PMID:
18458892
50.

4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.

Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, Kim JW, Aklillu E, Gustafsson LL, Bertilsson L.

Pharmacogenet Genomics. 2008 Mar;18(3):201-8. doi: 10.1097/FPC.0b013e3282f50ee9.

PMID:
18300941

Supplemental Content

Loading ...
Support Center